ICD-O-3 Morphology
        
    9946/3: Juvenile myelomonocytic leukemia
    
                    Effective
                    2001 and later
                
            
        Reportable
        for cases diagnosed 
    1978 and later
    
Primary Site(s)
        
    C421
    
Primary site must be bone marrow (C421)
        
                    Coding Manual:
                    
                        Hematopoietic Coding Manual (PDF)
                    
                
            
            
                Abstractor Notes
The peripheral blood and bone marrow are always involved; proliferation of the granulocytic and monocytic lineages. Blasts plus promonocytes account for <20% of PB and BM. Leukemic infiltrates are common in the skin. 
The physician will test to confirm that the Philadelphia chromosome and the BCR-ABL1 fusion gene are absent.
Although JMML rarely transforms into acute leukemia, it is a rapidly-fatal disease for most children if left untreated.
In the absence of effective treatment most children die from organ failure, such as respiratory failure, due to leukemic infiltration. Stem cell transplant can cure about half of the patients.
For more information, see the NCI website: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_26
    The physician will test to confirm that the Philadelphia chromosome and the BCR-ABL1 fusion gene are absent.
Although JMML rarely transforms into acute leukemia, it is a rapidly-fatal disease for most children if left untreated.
In the absence of effective treatment most children die from organ failure, such as respiratory failure, due to leukemic infiltration. Stem cell transplant can cure about half of the patients.
For more information, see the NCI website: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_26
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
    Grade
        
     
        
            Not Applicable
        
    
    
Module Rule
        None
    
Alternate Names
Juvenile chronic myelomonocytic leukemia
    JMML-like disorders in children with Noonan syndrome
    JMML in children with CBL syndrome
    JMML in neurofibromatosis type 1
    PTPN11-mutated JMML
    NRAS-mutated JMML
    KRAS-mutated JMML
    Definition
A rare form of childhood leukemia in which cancer cells often spread into tissues such as the skin, lung and intestines.
JMML is a clonal hematopoietic disorder of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages. Erythroid and megakaryocytic abnormalities frequently present, in keeping with evidence that JMML arises from a BM stem cell with multilineage potential in the myeloid series.
    JMML is a clonal hematopoietic disorder of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages. Erythroid and megakaryocytic abnormalities frequently present, in keeping with evidence that JMML arises from a BM stem cell with multilineage potential in the myeloid series.
Definitive Diagnostic Methods
Bone marrow biopsy
    Genetic testing
    Peripheral blood smear
    Genetics Data
Monosomy 7
    Immunophenotyping
        None
    
Treatments
Chemotherapy
    Hematologic Transplant and/or Endocrine Procedures
    Radiation therapy
    Surgery
    Transformations to
Transformations from
        None
    
Same Primaries
Corresponding ICD-9 Codes
206.1 Chronic monocytic leukemia
    Corresponding ICD-10 Codes
C93.1 Chronic monocytic leukemia
    Corresponding ICD-10-CM Codes (U.S. only)
C93.3 Juvenile myelomonocytic leukemia (effective October 01, 2015)
    Signs and Symptoms
Diagnostic Exams
Blood chemistry studies
    Bone marrow aspiration and biopsy
    
    Cytogenetic analysis
    Immunocytochemistry
    Peripheral blood smear
    
    Epidemiology and Mortality
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic/myeloproliferative neoplasms
Pages: 89-92
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic/myeloproliferative neoplasms
Pages: 89-92
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)
Pages: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_1
    Section: General Information About Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)
Pages: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_1
                
 Home